Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol

Lancet

Volumn 349, Issue 9064, 1997, Pages 1513-1515

  Condos, Rany ^a   Rom, William N ^a   Schluger, Neil W ^a,b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b BELLEVUE HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE; GAMMA INTERFERON;

AEROSOL; ARTICLE; BACTERIUM CULTURE; BODY WEIGHT; CELL ACTIVATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG EFFICACY; DRUG SAFETY; EFFECTOR CELL; FEMALE; HOST RESISTANCE; HUMAN; IMMUNITY; INHALATIONAL DRUG ADMINISTRATION; LUNG ALVEOLUS MACROPHAGE; LUNG CAVITATION; LUNG TUBERCULOSIS; MALE; MORBIDITY; MULTIDRUG RESISTANCE; MYALGIA; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SPUTUM SMEAR; T LYMPHOCYTE;

EID: 0030961425     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)12273-X     Document Type: Article

References (16)

1. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-32.
2. Park M, Davis AL, Schluger N, Cohen H, Rom WN. Outcome of MDR-TB patients, 1983-1993: prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996; 153: 317-24.
3. Yew WW, Chau CH. Drug-resistant tuberculosis in the 1990s. Eur Respir J 1995; 8: 1184-92.
4. Huebner RE, Castro KG. The changing face of tuberculosis. Annu Rev Med 1995; 46: 47-55.
5. Gallin JI, Farber JM, Holland SM, Nutman TB. Interferon-γ in the management of infectious diseases. Ann Intern Med 1995; 123: 216-24.
6. Vilcek J, Oliveira I. Recent progress in the elucidation of interferon-gamma actions: molecular biology and biological functions. Int Arch Allergy Immunol 1994; 104: 311-16.
7. Nathan CF, Prendergast TJ, Wiebe ME, et al. Activation of human macrophages. Comparison of other cytokines with interferon-γ. J Exp Med 1984; 160: 600-05.
8. Murray HW. Interferon-γ and host antimicrobial defense: current and future clinical applications. Am J Med 1994; 97: 459-67.
9. Chan J, Tanaka K, Carroll D, Flynn J, Bloom BR. Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect Immun 1995; 63: 736-40.
10. Kamijo R, Harada H, Matsuyama T, et al. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 1994; 263: 1612-15.
11. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart T A. Multiple defects of immune cell function in mice with disrupted γ-interferon genes. Science 1993; 259: 1739-42.
12. Huang S, Hendricks W, Althage A, et al. Immune response in mice that lack the interferon-γ receptor. Science 1993; 259: 1742.
13. Holland SM, Eisenstein E, Kuhns DB, et al. Treatment of refractory disseminated nontuberculosis mycobacterial infection with Interferon gamma. N Engl J Med 1994; 330: 1348-55.
14. Pfyffer GE, Kissling P, Jahn EMI, Welscher H-M, Salfinger M, Weber R. Diagnostic performance of amplified Mycobacterium tuberculosis direct test with cerebrospinal fluid, other nonrespiratory, and respiratory specimens. J Clin Microbiol 1996; 34: 834-41.
15. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon-gamma to prevent infection in chronic granulomatous disease. N Engl J Med. 1991; 321: 509-16.
16. Sampaio EP, Moreira AL, Sarno EN, Malta AM, Kaplan G. Prolonged treatment with recombinant Interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992; 175: 1729-37.